ea0090p137 | Pituitary and Neuroendocrinology | ECE2023
Thurmann Jorgensen Nanna
, Brun Boesen Victor
, Willemoes Borresen Stina
, Christoffersen Thea
, Rye Jorgensen Niklas
, Watt Torquil
, Feldt-Rasmussen Ulla
, Klose Marianne
Background and aim: The dual-release hydrocortisone Plenadren® has shown promising results of improved cardiovascular and metabolic profiles after treatment of adrenal insufficiency, possibly due to an improved circadian profile of cortisol, but results are ambiguous. Aim: To further investigate the potential effect of dual-release hydrocortisone on the metabolic profile as compared to conventional hydrocortisone in patients with secondary adrenal i...